Anti-angiogenic agents: Clinical trial design and therapies in development

European Journal of Cancer

Volumn 36, Issue 13, 2000, Pages 1713-1724

  Deplanque, G ^a   Harris, A L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Clinical trial; Drug evaluation; Neoplasms

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; CARBOPLATIN; CGS 27023A; COMBRETASTATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENDOTHELIN RECEPTOR ANTAGONIST; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; HYDROXAMIC ACID DERIVATIVE; INTEGRIN; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; RAZOXANE; REBIMASTAT; SOLIMASTAT; SQUALAMINE; SURAMIN; TANOMASTAT; TETRATHIOMOLYBDIC ACID; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINBLASTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW;

EID: 0033853171     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00149-0     Document Type: Article

References (102)

1. Folkman J. Tumor angiogenesis. therapeutic implications N. Engl. J. Med. 285:1971;1182-1186.
2. Jones A., Harris A.L. New developments in angiogenesis. a major mechanism for tumor growth and target for therapy Cancer J. 4:1998;209-217.
3. Arenberg D.A., Strieter R.M. Angiogenesis. Serhan C.N., Ward P.A. Molecular and Cellular Basis of Inflammation. 1999;29-49 Humana Press, Totowa.
4. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases. balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat. Med. 2:1996;689-692.
5. Bergers G., Hanahan D., Coussens L.M. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42:1998;995-1002.
6. McCawley L.J., Matrisian L.M. Matrix metalloproteinases. multifunctional contributors to tumor progression Mol. Med. Today. 6:2000;149-156.
7. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases. biologic activity and clinical implications J. Clin. Oncol. 18:2000;1135-1149.
8. Belotti D., Vergani V., Drudis T.et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
9. Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer agents targeting signaling molecules and cancer cell environment. challenges for drug development J. Natl. Cancer Inst. 91:1999;1281-1287.
10. Harris A.L. Antiangiogenesis for cancer therapy. Lancet. 349(Suppl. II):1997;13-15.
11. Macaulay V.M., O'Byrne K.J., Saunders M.P.et al. Phase I study of intrapleural Marimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5:1999;513-520.
12. Fuhrmann-Benzaken E., Ma M.N., Rubbia-Brandt L.et al. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int. J. Cancer. 85:2000;40-45.
13. Wynendaele W., Derua R., Hoylaerts R.et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers. a key to study an angiogenic marker in vivo? Ann. Oncol. 10:1999;965-971.
14. Jones P.H., Harris A.L. The current status of clinical trials in anti-angiogenesis. PPO update on Principles and Practice of Oncology. 14:2000;1-7.
15. 18F]-fluorodeoxyglucose and positron emission tomography. review and 1999 EORTC recommendations Eur. J. Cancer. 35:1999;1773-1782.
16. Pham C.D., Roberts T.P., Van Bruggen N.et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16:1998;225-230.
17. Sawicki W., Spiewankiewicz B., Cendrowski K., Stelmachow J. Transvaginal colour flow imaging in assessment of ovarian tumor neovascularization. Eur. J. Gynaecol. Oncol. 18:1997;407-409.
18. Miles K.A. Tumour angiogenesis and its relation to contrast enhancement on computed tomography. a review Eur. J. Radiol. 30:1999;198-205.
19. Kakeji Y., Teicher B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs. 15:1997;39-48.
20. Workman P, Aboagye E, Burtles S, et al. Development of novel pharmacokinetic and pharmacodynamic technologies for phase I clinical trials: The UK CRC experience and future plans. Proc 1999 AACR · NCI · EORTC International Conference, abstract 491.
21. Pezzella F., Di Bacco A., Andreola S., Nicholson A.G., Pastorino U., Harris A.L. Angiogenesis in primary lung cancer and lung secondaries. Eur. J. Cancer. 32A:1996;2494-2500.
22. Maniotis A.J., Folberg R., Hess A.et al. Vascular channel formation by human melanoma cells in vivo and in vitro. vasculogenic mimicry Am. J. Pathol. 155:1999;739-752.
23. Beitz J. Quality-of-life end points in oncology drug trials. Oncology (Huntingt). 13:1999;1439-1442.
24. Angiogenesis inhibitors in clinical trials. National Cancer Institute. http://cancertrials.nci.nih.gov/news/angio/table.html.
25. Clinical research protocols for selected new antitumor agents. http://www.moffitt.usf.edu/cancjrnl/v6n5/proto.htm.
26. Li C.Y., Shan S., Huang Q.et al. Initial stages of tumor cell-induced angiogenesis. evaluation via skin window chambers in rodent models J. Natl. Cancer Inst. 92:2000;143-147.
27. Folkman J. Incipient angiogenesis. J. Natl. Cancer Inst. 92:2000;94-95.
28. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis. a moving target for therapeutic intervention J. Clin. Invest. 103:1999;1237-1241.
29. Results of Marimastat study 128 - pancreatic cancer monotherapy trial. 1999, http://www.britbio.co.uk/news/128.txt.
30. Results of Marimastat study 145 in gastric cancer. 1999, http://www.britbio.co.uk/news/990824.txt.
31. Results of Marimastat study 193 in advanced pancreatic cancer. 2000, http://www.britbio.co.uk/news/193_results.txt.
32. D'Olimpio J, Hande K, Collier M, et al. Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999, 18, abstract 615.
33. Grochow L, O'Reilly S, Humphrey R, et al. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566. Proc Am Soc Clin Oncol 1998, 17, abstract 822.
34. Erlichman C, Adjei A, Alberts S, et al. Phase I study of BAY 12-9566, a matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 1998, 17, abstract 837.
35. Goel R, Hirte H, Major P et al. Clinical pharmacology of the metalloproteinase and angiogenesis inhibitor Bayer 12-9566 in cancer patients. Proc Am Soc Clin Oncol, 1999, 18, abstract 616.
36. Tolcher A, Rowinsky EK, Rizzo J et al. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay 12-9566 in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol, 1999, 18, abstract 617.
37. Rowinsky EK, Humphrey R, Hammond LA, et al. Phase I and pharmacologic study of the specific matrix metalloprotease inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000, 18, 178-186.
38. Golub L.M., Ramamurthy N.S., McNamara T.F.et al. Tetracyclines inhibit connective tissue breakdown. new therapeutic implications for an old family of drugs Crit. Rev. Oral. Biol. Med. 2:1991;297-321.
39. Lush L.M., Rudek M.A., Figg W.D. Review of three new agents that target angiogenesis, matrix metalloproteinases and cyclin-dependent kinases. Cancer Control. 6:1999;459-465.
40. Dupont E, Riviere M, Latreille J, Falardeau P, Blasecki J, Alaoui-Jamali M. Neovastat: an inhibitor of angiogenesis with anti-cancer activity. American Association for Cancer Research, Special Conference on Angiogenesis and Cancer, Orlando, USA, January 1998.
41. Evans WK, Latreille J, Batist G, et al. Æ-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 1938.
42. Brem S. Angiogenesis and cancer control. from concept to therapeutic trial Cancer Control. 6:1999;436-458.
43. Levitt NC, Eskens F, Propper DJ, et al. A phase I pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor. Proc Am Soc Clin Oncol 1998, 17, abstract 823.
44. Eskens F.A., Levitt N.C., Sparreboom A.et al. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloprotease inhibitor. Clin. Cancer Res. 6:2000;431-433.
45. Ferrara N., Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5:1999;1359-1364.
46. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 9:1999;211-220.
47. Gordon MS, Talpaz M, Margolin K, et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor in patients with metastatic cancer. Proc Am Soc Clin Oncol 1998, 17, abstract 809.
48. Margolin K, Gordon MS, Talpaz M, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in combination with chemotherapy in patients with advanced cancer: pharmacologic and long term safety data. Proc Am Soc Clin Oncol 1999, 18, abstract 1678.
49. Reese D, Frohlich M, Bok R, et al. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 1355.
50. Cropp G, Rosen L, Mulay M, Langecker P, Hannah A. Pharmacokinetics and pharmacodynamics of SU5416 in a phase I, dose escalating trial in patients with advanced malignancies. Proc Am Soc Clin Oncol 1999, 18, abstract 619.
51. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 1999, 18, abstract 618.
52. Shawver LK, Strawn LM, Fong TAT, et al. SU6668 is a potent, broad spectrum angiogenesis inhibitor that exhibits anti-tumor properties. Proc Am Assoc Cancer Res 1999, 40, abstract 4777.
53. Wood J.M., Bold G., Buchdunger E.et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189.
54. Bhargava P., Marshall J.L., Rizvi N.et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5:1999;1989-1995.
55. Stadler W.M., Kuzel T., Shapiro C., Sosman J., Clark J., Vogelzang N.J. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol. 17:1999;2541-2545.
56. Kudelka A.P., Levy T., Verschraegen C.F.et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3:1997;1501-1505.
57. Dezube B.J., Von Roenn J.H., Holden-Wiltse J.et al. Fumagillin analog in the treatment of Kaposi's sarcoma. a phase I AIDS clinical trial group study. AIDS clinical trial group No. 215 team J. Clin. Oncol. 16:1998;1444-1449.
58. Patnaik A, Rowinsky E, Hammond L, et al. A phase I and pharmacokinetic study of the unique angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc Am Soc Clin Oncol 1999, 18, abstract 622.
59. Bhargava P, Trocky N, Marshall J, et al. A Phase I safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion of MSI-1256f (squalamine lactate) in patients with advanced cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 623.
60. O'Reilly M.S., Boehm T., Shing Y.et al. Endostatin. an endogenous inhibitor of angiogenesis and tumour growth Cell. 88:1997;277-285.
61. Ryan P.R., Penson R.T., Ahmed S., Chabner B.A., Lynch J.T. Reality testing in cancer treatment. the phase I trial of endostatin Oncologist. 4:1999;501-508.
62. Gutheil JC, Campbell TN, Pierce PR, et al. Phase I study of Vitaxin, an antiangiogenic humanized monoclonal antibody to vascular integrin αvβ3. Proc Am Soc Clin Oncol 1998, 17, abstract 832.
63. Hanauske AR. Anti-angiogenesis drugs. Abstracts and Proceedings ECCO 10, 1999, abstract 1218.
64. DeVore R.F., Hellerqvist C.G., Wakefield G.B.et al. Phase I study of the antineovascularization drug CM101. Clin. Cancer Res. 3:1997;365-372.
65. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.Y., Smulson M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58:1998;4510-4514.
66. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J. Natl. Cancer Inst. 92:2000;520-522.
67. Quilitz R. Thalidomide in oncology. the peril and the promise Cancer Control. 6:1999;483-495.
68. Singhal S., Mehta J., Desikan R.et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:1999;1565-1571.
69. Durie B.G., Stepan D.E. Efficacy of low dose thalidomide in multiple myeloma. Elec. J. Oncol. 1:2000;1-8.
70. Fine H.A., Figg W.D., Jaeckle K.et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol. 18:2000;708-715.
71. Marx GM, Levi JA, Bell DR, et al. A phase I/II trial of thalidomide in the treatment of advanced cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 1751.
72. Glass J, Gruber ML, Nirenberg A. Phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme. Proc Am Soc Clin Oncol 1999, 18, abstract 551.
73. Watanabe S, Pituskin E, Calder K, Neumann CM, Bruera E. Thalidomide in the symptomatic treatment of cachexia in patients with terminal cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 180.
74. Politi P, Reboredo G, Losso M, Vujacich C, Schwartsmann G, Lewi D. Phase I trial of thalidomide in AIDS-related Kaposi sarcoma. Proc Am Soc Clin Oncol 1999, 18, abstract 161.
75. Figg WD, Bergan R, Brawley O, et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 1189.
76. Baidas SM, Isaacs C, Crawford J, et al. A phase II evaluation of thalidomide in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 475.
77. Eisen T., Boshoff C., Mak I.et al. Continuous low dose thalidomide. a phase II study in advanced melanoma, renal cell, ovarian and breast cancer Br. J. Cancer. 82:2000;812-817.
78. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000, 18, 716-723.
79. Small E.J., Meyer M., Marshall M.E.et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer. results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone J. Clin. Oncol. 18:2000;1440-1450.
80. Gradishar WJ, O'Regan RM, Liu J, et al. Phase II trial of suramin in metastatic breast cancer with an assessment of angiogenesis inhibition. Proc Am Soc Clin Oncol 1997, 16, abstract 600.
81. Grossman SA, Phuphanich S, Lesser G, et al. Efficacy, toxicity and pharmacology of suramin in adults with recurrent high grade astrocytomas. Proc Am Soc Clin Oncol 1999, 18, abstract 543.
82. De Vries EGE, Groen HJM, Wynendaele W, Lechuga MJ, Poggesi I, van Oosterom AT. PNU-145156E a novel angiogenesis inhibitor in patients with solid tumors: an update of a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 1999, 18, abstract 620.
83. Groen HJM, de Vries EGE, Wynendaele W, et al. Phase I and pharmacokinetic study of suradista (FCE26644) in patients with solid tumors. Proc Am Soc Clin Oncol 1998, 17, abstract 931.
84. Rabinovitz M. Angiogenesis and its inhibition. the copper connection J. Natl. Cancer Inst. 91:1999;1689-1690.
85. Brewer G.J., Dick R.D., Grover D.K.et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent. phase I study Clin. Cancer Res. 6:2000;1-10.
86. Lever A.F., Hole D.J., Gillis C.R.et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 352:1998;179-184.
87. Jones PH, Elliot M, Dobbs N, et al. Phase I/II study of combination antiangiogenesis therapy with Marimastat, captopril and fragmin. Proc Am Soc Clin Oncol 1999, 18, abstract 1723.
88. Kohn E.C., Figg W.D., Sarosy G.A.et al. Phase I trial of micronized formulation carboxyamido-triazole in patients with refractory solid tumors. pharmacokinetics, clinical outcome and comparison of formulations J. Clin. Oncol. 15:1997;1985-1993.
89. Bauer K.S., Figg W.D., Hamilton J.M.et al. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin. Cancer Res. 5:1999;2324-2329.
90. Carducci M, Bowling M, Rogers T, et al. ABT-627, an endothelin-receptor antagonist for refractory adenocarcinomas: phase I and pharmacologic evaluation. Proc Am Soc Clin Oncol 1999, 18, abstract 625.
91. Zonnenberg BA, Anbaum B, Kronemeier R, et al. Results of an initial phase I dose-escalation study of the endothelin-A receptor antagonist ABT-627 in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1999, 18, abstract 626.
92. Portielje J.E., Kruit W.H., Schuler M.et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5:1999;3983-3989.
93. Lenzi R, Kudelka AP, Verschraegen C, et al. Recombinant human interleukin-12 in patients with ovarian and gastro-intestinal cancers. Evidence of biological activity and lack of significant toxicity with low-dose intraperitoneal administration. Proc Am Soc Clin Oncol 1999, 18, abstract 1721.
94. Pfeffer L.M., Dinarello C.A., Herberman R.B.et al. Biological properties of recombinant alpha-interferons. 40th anniversary of the discovery of interferons Cancer Res. 58:1998;2489-2499.
95. Folkman J. Successful treatment of an angiogenic disease. N. Engl. J. Med. 320:1989;1211-1212.
96. Benjamin RS, Patel SR, Gutterman JU, et al. Interferon a2b as anti-angiogenic therapy of giant cell tumors of bone: implications for the study of newer angiogenesis inhibitors. Proc Am Soc Clin Oncol 1999, 18, abstract 2114.
97. Boehm R., Folkman J., Browder T.et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
98. Schulman P. Lack of resistance of hairy cell leukemia to interferon therapy. Proc Am Soc Clin Oncol 1998, 17, abstract 144.
99. Kerbel S.R. Tumor angiogenesis. past, present and future Carcinogenesis. 21:2000;505-515.
100. Browder T., Butterfield C.E., Kraling B.M.et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:2000;1878-1886.
101. Klement G., Baruchel S., Rak J.et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:2000;R15-R24.
102. O'Byrne KJ, Propper D, Braybrooke J, et al. Razoxane: a phase II trial in renal cell cancer evaluating anti-angiogenic activity. Proc Am Soc Clin Oncol 1997, 16, abstract 1160.